安洛替尼联合PD-1/PD-L1抑制剂治疗恶性实体瘤的疗效和安全性：荟萃分析和网络荟萃分析
Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors in malignant solid tumors: a meta-analysis and network meta-analysis.
摘要(中文译文)
评估安洛替尼联合程序性细胞死亡蛋白1/程序性死亡配体1（PD-1/PD-L1）抑制剂治疗恶性实体瘤的疗效和安全性。检索PubMed、Web of Science、Embase和Cochrane Library数据库，收集随机对照试验（RCT）、队列研究和单臂研究，比较安洛替尼联合PD-1/PD-L1抑制剂（联合组）与其他疗法（对照组）治疗恶性实体瘤的效果。搜索期从每个数据库的创建到2025年11月。确定了26项研究，涉及3263名患者。联合治疗组的客观反应率（ORR）为57%（95%CI:47%-67%），疾病控制率（DCR）为90%（95%CI:84%-93%）。不良反应的发生率包括疲劳（RR=1.196，95%CI:1.024-1.396）和低白蛋白血症（RR=1.336，95%CI：1.121-1.593）。与对照组相比，联合组显著改善了恶性实体瘤的ORR（RR=1.70，95%CI:1.29-2.25，P≤0.0001）、DCR（RR=1.08，95%CI=1.02-1.14，P=0.009）、总体生存率（OS）（HR=0.64，95%CI:0.54-0.76，P≤0.001）和无进展生存率（PFS）（HR=0.48，95%CI:0.39-0.59，P≤001）。联合用药组低白蛋白血症的发生率高于对照组。网络荟萃分析的结果表明，安洛替尼和TQB2450联合治疗的疗效更优。安洛替尼联合PD-1/PD-L1抑制剂在治疗多种肿瘤类型方面显示出显著疗效。安洛替尼和TQB2450的组合具有优势，但应注意低蛋白血症的发生。
Abstract
To evaluate the efficacy and safety of anlotinib combined with programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors in the treatment of malignant solid tumors. PubMed, Web of Science, Embase, and Cochrane Library databases were searched to collect randomized controlled trials (RCTs), cohort studies, and single-arm studies comparing anlotinib combined with PD-1/PD-L1 inhibitors (combination group) against other therapies (control group) for the treatment of malignant solid tumors. The search period spanned from the inception of each database to November 2025. 26 studies involving 3,263 patients were identified. The Objective Response Rate (ORR) in the combination group was 57% (95% CI: 47%-67%), with a Disease Control Rate (DCR) of 90% (95% CI: 84%-93%). The incidence of adverse reactions included fatigue (RR = 1.196, 95% CI: 1.024-1.396) and hypoalbuminemia (RR = 1.336, 95% CI: 1.121-1.593). Compared with the control group, the combination group significantly improved ORR in malignant solid tumors (RR = 1.70, 95% CI: 1.29-2.25, P ≤ 0.0001), DCR (RR = 1.08, 95% CI: 1.02-1.14, P = 0.009), Overall Survival (OS) (HR = 0.64, 95% CI: 0.54-0.76, P ≤ 0.001), and Progression Free Survival (PFS) (HR = 0.48, 95% CI: 0.39-0.59, P ≤ 0.001). The incidence of hypoalbuminemia was higher in the combination group than in the control group. Results from a network meta-analysis indicated superior efficacy for the combination of anlotinib and TQB2450. Anlotinib combined with PD-1/PD-L1 inhibitors demonstrates significant efficacy in treating multiple tumor types. The combination of anlotinib and TQB2450 offers advantages, but attention should be paid to the occurrence of hypoproteinemia.
如何引用
AMA
Chen Wang, Ning Wang, Zijing Wu, Xinjuan Yu, Xiaolu Yu, Jing Wang, et al. Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors in malignant solid tumors: a meta-analysis and network meta-analysis.. Frontiers in immunology. 2026; doi:10.3389/fimmu.2026.1780636.
APA
Chen Wang, Ning Wang, Zijing Wu, Xinjuan Yu, Xiaolu Yu, Jing Wang, et al (2026). Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors in malignant solid tumors: a meta-analysis and network meta-analysis.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1780636
GB/T 7714
Chen Wang, Ning Wang, Zijing Wu, Xinjuan Yu, Xiaolu Yu, Jing Wang, et al. Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors in malignant solid tumors: a meta-analysis and network meta-analysis.[J]. Frontiers in immunology, 2026 doi:10.3389/fimmu.2026.1780636.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出